This is a working overview of immunomodulator, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-15 and is reviewed periodically as new material appears.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
==== Anti-Coercion Instrument ==== Several European leaders including France's Emmanuel Macron advocated using the EU's Anti-Coercion Instrument, a security and trade policy tool known as the "trade bazooka", to target the United States in retaliation. Under the not-previously-used instrument, the EU may adopt countermeasures, sometimes described as sanctions, including tariffs, restrictions on public procurement, and measures affecting trade and investment. Bernd Lange, chair of the European Parliament Committee on International Trade, supported its activation. By 21 January EU countries were described as being increasingly open to using the ACI against the United States, with Germany stating it will ask the Commission to explore its use.
Measurement tools, such as goniometers and inclinometers, aid in standardized quantification of joint motion relative to normative values or ranges. Tests that follow functional movements, such as reaching overhead, squatting, or rotating the neck, are used to evaluate whether reduced ROM translates into activity limitation. When hypomobility is regional, clinicians can use condition-specific values to compare the patient's ROM values against. For instance, in the shoulder, adhesive capsulitis (frozen shoulder) is defined by marked loss of both active and passive motion (particularly external rotation and abduction). For the knee, postoperative arthrofibrosis is typically diagnosed when extension loss exceeds 10° or flexion is limited to less than 100°, with more severe forms showing a flexion deficit of 25° or greater. In the spine, decreased ROM is assessed using values developed for ankylosing spondylitis and related disorders. The Modified Schober Test measures lumbar flexion. An increase of less than 5 cm indicates limited motion, chest expansion of 2.5 cm or less suggests thoracic restriction, and an occiput-to-wall distance greater than 2 cm shows thoracic or cervical extension limitation. The Bath Ankylosing Spondylitis Metrology Index (BASMI) provides a composite score summarizing these spinal mobility measures and is widely used to quantify skeletal hypomobility.
An antifreeze is an additive which lowers the freezing point of a water-based liquid. An antifreeze mixture is used to achieve freezing-point depression for cold environments. Common antifreezes also increase the boiling point of the liquid, allowing higher coolant temperature. However, all common antifreeze additives also have lower heat capacities than water, and do reduce water's ability to act as a coolant when added to it. Because water has good properties as a coolant, water plus antifreeze is used in internal combustion engines and other heat transfer applications, such as HVAC chillers and solar water heaters. The purpose of antifreeze is to prevent a rigid enclosure from bursting due to expansion when water freezes. Commercially, both the additive (pure concentrate) and the mixture (diluted solution) are called antifreeze, depending on the context. Careful selection of an antifreeze can enable a wide temperature range in which the mixture remains in the liquid phase, which is critical to efficient heat transfer and the proper functioning of heat exchangers. Most if not all commercial antifreeze formulations intended for use in heat transfer applications include anti-corrosion and anti-cavitation agents (that protect the hydraulic circuit from progressive wear).
Amino acid replacement is a change from one amino acid to a different amino acid in a protein due to point mutation in the corresponding DNA sequence. It is caused by a nonsynonymous missense mutation which changes the codon sequence to code for a different amino acid than the original sequence.
The CBO forecast in April 2020 that the budget deficit in fiscal year 2020 would be $3.7 trillion (17.9% GDP), versus the January estimate of $1 trillion (4.6% GDP). CBO also forecast the unemployment rate would rise to 16% by Q3 2020 and remain above 10% in both 2020 and 2021.
Sources: en.wikipedia.org
=== COVID-19 === NUVAXOVID is a recombinant subunit vaccine licensed for the prevention of SARS-CoV-2 infection. Market authorization was issued on 20 December 2021. The vaccine contains the SARS-CoV-2 spike protein produced using the baculovirus expression system, which is eventually adjuvanted with the Matrix M adjuvant.
While BIA Separations was the first to commercially market polymeric monoliths, Merck KGaA was the first company to market silica monoliths. In 1996, Tanaka and coworkers at the Kyoto Institute of Technology published extensive work on silica monolith technologies. Merck was later issued a license from Kyoto Institute of Technology to develop and produce the silica monoliths. Promptly thereafter, in 2001, Merck introduced its Chromolith line of monolithic HPLC columns at analytical instrumentation trade show PittCon. Initially, says Karin Cabrera, senior scientist at Merck, the high flow rate was the selling point for the Chromolith line. Based on customer feedback, though, Merck soon learned that the columns were more stable and longer-lived than particle-packed columns. The columns were the recipients of various new product awards. Difficulties in production of the silica monoliths and tight patent protection have precluded attempts by other companies at developing a similar product. It has been noted that there are more patents concerning how to encapsulate the silica rod than there are on the manufacture of the silica itself. Historically, Merck has been known for its superior chemical products, and, in liquid chromatography, for the purity and reliability of its particulate silica. Merck is not known for its LC columns. Five years after the introduction of its Chromolith line, Merck made a very strategic marketing decision.
Produced by Sandy Balfour, made by Double Exposure 4 October Homes on Wheels, about the one in twelve Americans, who live in a mobile home; Allan Wallis; David Thornburg (Galloping Bungalows), and the Tin Can Tourists in 1919; Randall Henderson; Glenn Curtiss Aerocar; Arthur Sherman in the 1930s; the Airstream from William Bowlus of Ryan Aircraft, originally made by Bowlus-Teller then by Wally; designer William Stout; Wilbur Bontrager of Jayco; Lazydays and the Family Motor Coach Association. Directed by George Haggerty, produced by Mike Wallington, made by Kai Productions 11 October Born That Way?, about the work of the homosexual British neuroscientist Simon LeVay, meeting a religious opponent of homosexuality, and a psychotherapist who thought that being homosexual was a mental illness; the Salk Institute for Biological Studies, and work on the INAH 3 in the hypothalamus; the work of Magnus Hirschfeld; endocrinologist Günter Dörner of the Humboldt University of Berlin; Louis P. Sheldon of the Traditional Values Coalition, did not approve of any promotion of homosexuality; until 1973 in the US, homosexuality was regarded as a deviant sexual predilection, and thought to be a mental illness; many US psychiatrists thought homosexuality to be a type of mental disorder, notably Charles W. Socarides; Richard Green (sexologist); Dulwich College; psychiatrist Richard Pillard; psychologist J.
== Biosynthesis == Proline is biosynthetically derived from the amino acid L-glutamate. Glutamate-5-semialdehyde is first formed by glutamate 5-kinase (ATP-dependent) and glutamate-5-semialdehyde dehydrogenase (which requires NADH or NADPH). This can then either spontaneously cyclize to form 1-pyrroline-5-carboxylic acid, which is reduced to proline by pyrroline-5-carboxylate reductase (using NADH or NADPH), or turned into ornithine by ornithine aminotransferase, followed by cyclisation by ornithine cyclodeaminase to form proline.
Sources: en.wikipedia.org
Codeine-6-glucuronide (C6G) is a major active metabolite of codeine and may be responsible for as much as 60% of the analgesic effects of codeine. C6G exhibits decreased immunosuppressive effects compared to codeine.
=== The Buck Institute for Research on Aging === In November 2016, Verdin became president and CEO of the Buck Institute for Research on Aging. The Buck Institute is the first independent research center focused solely on aging. As of 2022, it had an operating budget of $65 million a year and around 300 employees. The Buck's first human clinical trial, Buck Institute Ketone Ester (BIKE), was announced in 2023. In 2025, Verdin was named a scientific ambassador for Alliance for Longevity Science, Arts & Entertainment (ALSAE), a partner organization of the Buck Institute.
=== "Original Recipe" and franchising === In July 1940, Sanders finalized what came to be known as his "Original Recipe" of 11 herbs and spices. Although he never publicly revealed the recipe, he said the ingredients included salt and pepper and that the rest "stand on everybody's shelf". After being recommissioned as a Kentucky Colonel in 1950 by Governor Lawrence Wetherby, Sanders began to dress the part, growing a goatee, wearing a black frock coat (later switched to a white suit) and a string tie and referring to himself as "the Colonel". His associates went along with the title change, "jokingly at first and then in earnest", according to biographer Josh Ozersky. In 1952, Sanders franchised his recipe to his friend Pete Harman of South Salt Lake, Utah, the operator of one of the city's largest restaurants. The Sanders Court & Café generally served travelers, so when the route planned in 1955 for Interstate 75 bypassed his properties, Sanders sold them and traveled the US to franchise his recipe to restaurant owners. Independent restaurants would pay four (later five) cents on each chicken as a franchise fee in exchange for Sanders' recipe and the right to feature it on their menus and use his name and likeness for promotional purposes. Don Anderson, a sign painter hired by Harman, coined the name "Kentucky Fried Chicken". For Harman, the addition of KFC was a way of differentiating his restaurant from competitors; a product from Kentucky was exotic and evoked imagery of Southern hospitality.
== Service == Mrksich has also been active in serving the scientific community in a number of roles. These include his current service as the Scientific Director of the Searle Scholars Program, as a member of the Board of Governors for Argonne National Laboratory, and as a member of the Board of Directors for the Camille & Henry Dreyfus Foundation. His past appointments include service and chairing DARPA’s Defense Sciences Research Council and many program advisory committees.
By the mid-1990s, several GH companies had sponsored or publicized research into the quality of life of adults with severe GH deficiency. Most were people having been treated with GH in childhood for severe deficiency. Many of them stopped injections as they reached their final heights in the low-normal range. However, as adults in their 30s and 40s, these people, who had been children with growth hormone deficiency, were now adults with growth hormone deficiency and had more than their share of common adult problems: reduced physical, mental, and social energy, excess adipose and diminished muscle, diminished libido, poor bone density, higher cholesterol levels, and higher rates of cardiovascular disease. Research trials soon confirmed that a few months of GH could improve nearly all of these parameters. However, despite marketing efforts, most GH-deficient adults remain untreated. Though GH use was slow to be accepted among adults with GH deficiency, similar research to see if GH treatment could slow or reverse some of the similar effects of aging attracted much public interest. The most publicized trial was reported by Daniel Rudman in 1990. As with other types of hormone supplementation for aging (testosterone, estrogen, DHEA), confirmation of benefit and accurate understanding of risks has been only slowly evolving. In 1997, Ronald Klatz of the American Academy of Anti-Aging Medicine published Grow Young With HGH: The Amazing Medically Proven Plan To Reverse the Effects Of Aging, an uncritical touting of GH as the answer to aging.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.